173 related articles for article (PubMed ID: 32699671)
21. Analysis of US Food and Drug Administration Warning Letters: False Promotional Claims Relating to Prescription and Over-the-Counter Medications.
Salas M; Martin M; Pisu M; McCall E; Zuluaga A; Glasser SP
Pharmaceut Med; 2008 Mar; 22(2):. PubMed ID: 24353430
[TBL] [Abstract][Full Text] [Related]
22. Analysis of FDA Warning Letters Issued to Indian Pharmaceutical and Medical Device Companies: A Retrospective Study.
Bablani S; Janodia MD
Ther Innov Regul Sci; 2020 Jul; 54(4):925-931. PubMed ID: 32557315
[TBL] [Abstract][Full Text] [Related]
23. Early Phase in the Development of Cannabidiol as a Treatment for Addiction: Opioid Relapse Takes Initial Center Stage.
Hurd YL; Yoon M; Manini AF; Hernandez S; Olmedo R; Ostman M; Jutras-Aswad D
Neurotherapeutics; 2015 Oct; 12(4):807-15. PubMed ID: 26269227
[TBL] [Abstract][Full Text] [Related]
24. A Retrospective Analysis of Clinical Research Misconduct Using FDA-Issued Warning Letters and Clinical Investigator Inspection List From 2010 to 2014.
Romano CA; Nair S; Delphin ES
Anesth Analg; 2018 Mar; 126(3):976-982. PubMed ID: 29239950
[TBL] [Abstract][Full Text] [Related]
25. FDA Warning Letters: A Retrospective Analysis of Letters Issued to Pharmaceutical Companies from 2010-2020.
Rathore AS; Li Y; Chhabra H; Lohiya A
J Pharm Innov; 2022 Aug; ():1-10. PubMed ID: 35992018
[TBL] [Abstract][Full Text] [Related]
26. Molecular Targets of Cannabidiol in Neurological Disorders.
Ibeas Bih C; Chen T; Nunn AV; Bazelot M; Dallas M; Whalley BJ
Neurotherapeutics; 2015 Oct; 12(4):699-730. PubMed ID: 26264914
[TBL] [Abstract][Full Text] [Related]
27. Analysis of FDA Warning Letters Issued to Indian Pharmaceutical and Medical Device Companies: A Retrospective Study.
Bablani S; Janodia MD
Ther Innov Regul Sci; 2019 Nov; ():2168479019879380. PubMed ID: 31690096
[TBL] [Abstract][Full Text] [Related]
28. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal cannabis--GW pharmaceuticals, THC:CBD.
Drugs R D; 2003; 4(5):306-9. PubMed ID: 12952500
[TBL] [Abstract][Full Text] [Related]
29. Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: Practical experiences in a tertiary medical center.
Porcari GS; Fu C; Doll ED; Carter EG; Carson RP
Epilepsy Behav; 2018 Mar; 80():240-246. PubMed ID: 29429908
[TBL] [Abstract][Full Text] [Related]
30. The legal status of cannabis (marijuana) and cannabidiol (CBD) under U.S. law.
Mead A
Epilepsy Behav; 2017 May; 70(Pt B):288-291. PubMed ID: 28169144
[TBL] [Abstract][Full Text] [Related]
31. Cannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial.
Hurd YL; Spriggs S; Alishayev J; Winkel G; Gurgov K; Kudrich C; Oprescu AM; Salsitz E
Am J Psychiatry; 2019 Nov; 176(11):911-922. PubMed ID: 31109198
[TBL] [Abstract][Full Text] [Related]
32. Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy.
Samanta D
Pediatr Neurol; 2019 Jul; 96():24-29. PubMed ID: 31053391
[TBL] [Abstract][Full Text] [Related]
33. The Impact of Cannabidiol on Psychiatric and Medical Conditions.
Oberbarnscheidt T; Miller NS
J Clin Med Res; 2020 Jul; 12(7):393-403. PubMed ID: 32655732
[TBL] [Abstract][Full Text] [Related]
34. A Cross-Sectional Study of Cannabidiol Users.
Corroon J; Phillips JA
Cannabis Cannabinoid Res; 2018; 3(1):152-161. PubMed ID: 30014038
[No Abstract] [Full Text] [Related]
35. Cannabidiol as a Potential Treatment for Anxiety Disorders.
Blessing EM; Steenkamp MM; Manzanares J; Marmar CR
Neurotherapeutics; 2015 Oct; 12(4):825-36. PubMed ID: 26341731
[TBL] [Abstract][Full Text] [Related]
36. Clinicians' Guide to Cannabidiol and Hemp Oils.
VanDolah HJ; Bauer BA; Mauck KF
Mayo Clin Proc; 2019 Sep; 94(9):1840-1851. PubMed ID: 31447137
[TBL] [Abstract][Full Text] [Related]
37. The Surprising Reach of FDA Regulation of Cannabis, Even After Descheduling.
O'Connor SM; Lietzan E
Am Univ Law Rev; 2019; 68(3):823-925. PubMed ID: 30919712
[TBL] [Abstract][Full Text] [Related]
38. Long-term cannabidiol treatment prevents the development of social recognition memory deficits in Alzheimer's disease transgenic mice.
Cheng D; Spiro AS; Jenner AM; Garner B; Karl T
J Alzheimers Dis; 2014; 42(4):1383-96. PubMed ID: 25024347
[TBL] [Abstract][Full Text] [Related]
39. Content Analysis of 2012-2019 FDA Warning Letters and Notices of Violations using the Economic, Clinical, and Humanistic Outcomes (ECHO) Model.
Mohite N; Funtanilla V; Muzumdar J; Park T
Innov Pharm; 2021; 12(1):. PubMed ID: 34007685
[TBL] [Abstract][Full Text] [Related]
40. Neuronal and molecular effects of cannabidiol on the mesolimbic dopamine system: Implications for novel schizophrenia treatments.
Renard J; Norris C; Rushlow W; Laviolette SR
Neurosci Biobehav Rev; 2017 Apr; 75():157-165. PubMed ID: 28185872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
